



GP-1812  
646  
HS  
PATENT  
2257-1-001  
B3/11/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : ANDREW WILLIAM HEATH  
*8/878348*

SERIAL NO. : 08/873,348 EXAMINER : E. LAZAR-WESLEY

FILED : JUNE 18, 1997 ART UNIT : 1812  
*RECEIVED*  
*16C*

FOR : NOVEL VACCINE DEVELOPMENT MAR - 4 1998  
*2/19*

Certificate of Mailing Under 37 CFR 1.8

MATRIX CUSTOMER  
SERVICE CENTER

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on February 20, 1998.

David A. Jackson, Reg. No. 26,742  
(Name of Registered Rep.)

*David A. Jackson 2/20/98*  
(Signature and Date)

RESPONSE TO REQUIREMENT FOR RESTRICTION  
UNDER 35 U.S.C. §121

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Dear Sir:

Responsive to the Office Action dated January 21, 1998, issued in connection with the above-identified Application, which is now due for response on February 20, 1998, please consider the following remarks.

REMARKS

By this Office Action, the Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

Group I. Claims 1-16, drawn to an adjuvant, a vaccine and the manufacture of a vaccine, classified in class 424, subclass 184.1.